Credit Risk Management - The company has established strict credit risk management and internal control procedures for its lending transactions[3] - The credit risk assessment process includes evaluating the financial status, loan purpose, shareholder background, and business reputation of new clients[3] - The company conducts regular reviews of overdue amounts and takes follow-up actions to minimize credit risk[6] - The financial department prepares monthly aging analysis of debtors to closely monitor credit risk[6] - The company emphasizes the importance of due diligence and creditworthiness in its lending practices[3] Loan Approval Process - The management team is responsible for approving smaller loan amounts, while larger loans require board discussion and approval[5] - Any potential loans involving related parties will be reported to the board for assessment and compliance with listing rules[5] - The company aims to ensure that all lending transactions align with the overall interests of the company and its shareholders[5] Overdue Payment Handling - The company has implemented a structured procedure for handling overdue payments, including reminders and collection actions[6] - The financial department reports the status of the loan portfolio to the CEO monthly for monitoring purposes[6]

Financial Performance - The company's revenue for the six months ended June 30, 2022, was HKD 64.6 million, a decrease of approximately 54.2% from HKD 141.1 million for the same period in 2021[8]. - Gross profit for the same period was HKD 44.1 million, down 29.0% from HKD 62.1 million in 2021, while the gross profit margin increased from 44.0% to 68.2%[11]. - The company reported a profit attributable to owners of the company of HKD 10.6 million for the six months ended June 30, 2022, compared to HKD 43.2 million in 2021[9]. - The after-tax profit for the six months ended June 30, 2022, was HKD 10.4 million, a decrease of 76.0% compared to HKD 43.3 million for the same period in 2021[18]. - The total comprehensive loss for the period amounted to HKD 42,301,000, compared to a total comprehensive income of HKD 38,430,000 in 2021[140]. - The company reported a net profit of HKD 10,562,000 for the six months ended June 30, 2022, compared to HKD 43,190,000 for the same period in 2021, indicating a significant decrease[200]. Revenue Breakdown - The decline in revenue was primarily due to a downturn in the real estate market in mainland China, leading to a decrease in sales of construction materials and property sales by HKD 65.8 million and HKD 17.9 million, respectively[8]. - Revenue from the healthcare-related business increased 3.2 times to HKD 37.9 million, with profit rising 8.8 times to HKD 27.5 million, primarily due to the launch of the skincare brand "肌小簡" in the second half of 2021[19]. - Revenue from the trading business decreased by 84.9% to HKD 11.7 million, with profit down 41.5% to HKD 9.3 million, mainly due to the overall downturn in the real estate market in mainland China[22]. - Revenue from the sales agency business fell by 82.5% to HKD 3.8 million, resulting in a loss of HKD 0.1 million, attributed to the sluggish real estate market in mainland China[23]. - Revenue from the industrial hemp business plummeted by 98.7% to HKD 0.3 million, with a loss of HKD 2.1 million, due to the ban on industrial hemp in cosmetics in mainland China[26]. - Revenue from the sale of healthcare-related products was HKD 33,841,000 for the six months ended June 30, 2022, compared to HKD 20,000 for the same period in 2021, showing a substantial increase[183]. Operating Expenses and Costs - Operating expenses for the six months ended June 30, 2022, were HKD 17.2 million, a reduction of 22.9% from HKD 22.3 million in 2021, attributed to effective cost control measures[15]. - Financing costs increased to HKD 4.9 million, up 14.0% from HKD 4.3 million in 2021, primarily due to an increase in the average balance of bank loans[16]. - The company incurred financing costs of HKD 4,890,000 during the reporting period[183]. Assets and Liabilities - Non-current assets decreased to HKD 823.6 million as of June 30, 2022, down HKD 37.7 million from HKD 861.3 million at the end of 2021[28]. - Total liabilities increased to HKD 373.5 million as of June 30, 2022, up HKD 67.2 million from HKD 306.3 million at the end of 2021, primarily due to an increase in bank loans[31]. - Total net assets decreased to HKD 1,354.0 million as of June 30, 2022, down HKD 76.7 million from HKD 1,430.7 million at the end of 2021, mainly due to share buybacks and foreign exchange losses[32]. - Current assets were HKD 903,973,000, an increase from HKD 869,690,000 at the end of 2021[142]. - Total liabilities as of June 30, 2022, were HKD 260,590,000, compared to HKD 195,489,000 at the end of 2021[144]. Cash Flow - As of June 30, 2022, the group's cash and cash equivalents totaled HKD 138.9 million, a decrease from HKD 272.6 million as of December 31, 2021[34]. - For the six months ended June 30, 2022, net cash generated from operating activities was HKD 68.0 million, primarily due to cash inflows from daily operations[35]. - The net cash used in investing activities was HKD 242.7 million, mainly due to short-term interest loans of HKD 345.6 million to independent third parties[35]. - The cash and cash equivalents decreased by HKD 126,032 thousand, contrasting with an increase of HKD 32,586 thousand in the same period last year[149]. Strategic Focus and Future Plans - The company plans to continue focusing on health-related products and expand its market presence in response to changing consumer demands[12]. - The company aims to leverage its R&D, brand, and channel advantages in skin health management to develop effective skincare products and medical beauty combined business models[68]. - The company is actively pursuing clinical research collaborations with several hospitals, completing 17 case enrollments despite challenges posed by the COVID-19 pandemic[73]. - The company is focusing on expanding its industrial hemp business, with a strategic investment in CBD vaporizer technology and the launch of the high-end health consumer brand AlpReleaf in Europe[75]. - The company aims to build a sustainable revenue growth source by maintaining its leading position in the industrial hemp value chain[76]. Corporate Governance and Compliance - The company has adopted the principles of the Corporate Governance Code as per the Listing Rules Appendix 14[118]. - The audit committee consists of two independent non-executive directors and one non-executive director, overseeing financial reporting and internal controls[120]. - The company has confirmed compliance with the standards set forth in the Model Code for Securities Transactions by Directors of Listed Issuers[119]. Stock Options and Shareholder Information - A total of 12,603,000 stock options were granted to twelve participants under the 2019 stock option plan[89]. - The stock options granted to directors of investment entities are contingent upon achieving specific performance targets related to drug development and financial performance by 2020, 2022, and 2023[92]. - The total number of stock options granted to nine directors and senior management is 1,512,000, which do not require performance targets[94]. - The company has a total of 427,175,263 shares available for issuance under the 2019 stock option plan, representing approximately 10% of the issued share capital as of the interim report date[97].

Market Overview - The Chinese health market reached a scale of RMB 13 trillion in 2020, making it the second largest globally[23]. - In 2021, China's GDP per capita was RMB 80,976, equivalent to approximately USD 12,551, surpassing the global average[23]. Company Strategy and Investments - The company has strategically invested in Yinguang Biotechnology and established Meikang in 2020 to enhance its position in cell therapy and immune therapy[26]. - The company is focusing on skin health management, developing effective skincare products and combining them with medical aesthetics[24]. - Yinguang Biotechnology has made significant progress in stem cell drug development, establishing multiple product pipelines for various diseases[27]. - The company has received a new invention patent for a CAR-T technology that shows improved binding and efficacy compared to traditional methods[28]. - The Shenzhen government has prioritized legislation for cell and gene industries, indicating strong local support for the sector[26]. - The company is positioned to leverage its first-mover advantage in the cell therapy industry as supportive policies are implemented[27]. - The company aims to drive growth through technological advancements and professional services in health and beauty[24]. - The company is committed to long-term development in the health industry, aligning with national strategies like "Healthy China 2030" and the 14th Five-Year Plan[24]. Financial Performance - The company's revenue for the year ended December 31, 2021, was HKD 253.0 million, a decrease of approximately 4.6% from HKD 265.1 million in 2020[43]. - Gross profit for the year was HKD 100.9 million, down 9.3% from HKD 111.3 million in 2020, with a gross margin decline from 42.0% to 39.9%[44]. - Other income and net gains decreased by 32.2% to HKD 21.9 million, primarily due to unfavorable foreign exchange impacts, shifting from a gain of HKD 5.2 million in 2020 to a loss of HKD 9.9 million in 2021[46]. - Total operating expenses were HKD 42.7 million, a reduction of 15.3% from HKD 50.4 million in 2020, mainly due to the sale of clinics in Hong Kong and Shanghai[47]. - Financing costs decreased by 38.7% to HKD 8.4 million, attributed to a reduction in average bank loan balances compared to 2020[48]. - Profit after tax for the year was HKD 60.5 million, a decrease of 28.9% from HKD 85.1 million in 2020, primarily due to the absence of one-time gains recorded in the previous year[49]. Business Segments - Revenue from the industrial hemp business increased by 4.3% to HKD 26.5 million, with segment profit rising 35.0% to HKD 5.4 million[51]. - Revenue from healthcare-related businesses decreased by 48.0% to HKD 28.5 million, with segment profit declining 14.9% to HKD 12.0 million[52]. - Trade business revenue increased by 9.6% to HKD 146.8 million, but segment profit decreased by 35.0% to HKD 14.7 million due to various financial impacts[54]. Asset and Liabilities - The group's non-current assets increased to HKD 861.3 million as of December 31, 2021, from HKD 742.7 million in 2020, primarily due to an increase in fair value investments[64]. - Total current assets decreased to HKD 875.7 million as of December 31, 2021, from HKD 960.2 million in 2020, mainly due to a reduction in prepayments and other receivables[64]. - The group's total liabilities increased to HKD 306.3 million as of December 31, 2021, from HKD 299.6 million in 2020, primarily due to an increase in bank loans[64]. - The group's net asset value increased to HKD 1,430.7 million as of December 31, 2021, from HKD 1,403.3 million in 2020, driven by a profit of HKD 60.5 million for the year[65]. Cash Flow and Investments - The net cash used in operating activities was HKD 83.3 million for the year ended December 31, 2021, primarily for working capital needs[67]. - The net cash generated from investing activities was HKD 161.6 million, mainly from fund and financial product investments[70]. - The group has 100% ownership of a residential development project in Australia, with approximately 80% of the civil works completed as of December 31, 2021[58]. - The group's investment portfolio increased to HKD 315.0 million as of December 31, 2021, up from HKD 193.1 million in 2020, reflecting a strategic focus on health-related investments[84]. Employee and Governance - The employee count increased to 138 as of December 31, 2021, from 116 in 2020, reflecting growth in operations[87]. - The company emphasizes the importance of employee relations, offering competitive compensation and continuous training programs[101]. - The company has adopted a stock option plan to attract and retain key employees[101]. - The company has established service contracts with its directors, with terms ranging from one to three years, allowing for termination with written notice[141]. - The company has not established a corporate governance committee; thus, the board is responsible for executing corporate governance functions[190]. Shareholder Information - As of December 31, 2021, the total shares held by Mr. Zhou Xuzhou amounted to 2,251,534,761 shares, representing 53.43% of the issued shares[144]. - Dr. Zeng Wentao holds 75,000,000 shares, which accounts for 1.78% of the issued shares[144]. - The major shareholder U-Home Group International Limited holds 964,172,530 shares, representing 22.88% of the issued shares[153]. - The total amount of distributable reserves as of December 31, 2021, was HKD 361,216,000, an increase from HKD 342,662,000 in 2020[131]. Corporate Governance and Compliance - The company has adopted the corporate governance code principles and complied with all applicable code provisions during the fiscal year ending December 31, 2021[184]. - The board held four meetings during the fiscal year to discuss and formulate the overall strategy and review financial performance[189]. - All independent non-executive directors have confirmed their independence in accordance with the listing rules[188]. - The company has a policy in place for reviewing dividend policies[196].

美 瑞 健 康 国 际 产 业 集 团 Meilleure Health International Industry Group Meilleure Health International Industry Group Limited 美瑞健康國際產業集團有限公司 ( 於百慕達註冊成立之有限公司 ) (股份代號：2327) 中期報告２０２１ 一份專注 兩倍用心 三倍高效 十重保障 百倍體驗 終身受益 美瑞健康——精準健康管理 目錄 管理層討論及分析 3 其他資料 16 董事及高級管理人員履歷 23 獨立審閱報告 26 中期簡明綜合損益表 28 中期簡明綜合全面收益表 29 中期簡明綜合財務狀況表 30 中期簡明綜合權益變動表 32 中期簡明綜合現金流量表 33 中期簡明綜合財務報表附註 34 1 公司資料 2 中期報告 2021 美瑞健康國際產業集團有限公司 公司資料 | --- | --- | |---------------------------------|------------------------------------------------| | 董事會 | 註冊辦事處 | | 執行董 ...

美 瑞 健 康 国 际 产 业 集 团 Meilleure Health International Industry Group 美瑞健康國際產業集團有限公司 ( 於 百 慕 達 註 冊 成 立 之 有 限 公 司 ) (股份代號 : 2327) 2020 年報 一份專注 兩倍用心 三倍高效 十重保障 百倍體驗 終身受益 美瑞健康——精準健康管理 目錄 | --- | --- | |--------------------------|-------| | | | | 公司資料 | 2 | | 聯席主席報告書 | 3 | | 管理層討論與分析 | 9 | | 董事會報告 | 20 | | 企業管治報告 | 34 | | 環境、社會及管治報告 | 48 | | 董事及高級管理層履歷 | 97 | | 獨立核數師報告 | 100 | | 經審核綜合財務報表 | | | 綜合損益表 | 104 | | 綜合損益及其他全面收益表 | 105 | | 綜合財務狀況表 | 106 | | 綜合權益變動表 | 108 | | 綜合現金流量表 | 109 | | 綜合財務報表附註 | 111 | | 五年財務摘要 | 20 ...

--- 美 瑞 健 康 国 际 产 业 集 团 Meilleure Health International Industry Group Meilleure Health International Industry Group Limited 美瑞健康國際產業集團有限公司 (於百慕達註冊成立之有限公司) (股份代號 : 2327) 一份專注 兩倍用心 三倍高效 十重保障 百倍體驗 終身受益 美瑞健康——精準健康管理 中 期 報 告 2020 目錄 公司資料 2 管理層討論及分析 3 其他資料 29 董事及高級管理人員履歷 45 獨立審閱報告 51 中期簡明綜合損益表 53 中期簡明綜合全面收益表 54 55 | --- | --- | |-------|------------------------| | | | | | 中期簡明綜合財務狀況表 | | | 中期簡明綜合權益變動表 | | | 中期簡明綜合現金流量表 | | | | 57 58 中期簡明綜合財務報表附註 59 1 美瑞健康國際產業集團有限公司 | --- | --- | |--------------------------------- ...

美 瑞 健 康 国 际 产 业 集 团 Meilleure Health International Industry Group Meilleure Health International Industry Group Limited 美瑞健康國際產業集團有限公司 (Incorporated in Bermuda with limited liability) ( 於 百 慕 達 註 冊 成 立 之 有 限 公 司 ) (Stock Code 股份代號 : 2327) 一份 专注 两倍 用心 三倍 高效 十重 保障 百倍 体验 终身 受益 美瑞健康一 一 精准健康管理 2019 Annual Report 年報 CONTENTS 目錄 | --- | --- | |------------------------------------------------|----------------------| | | | | CORPORATE INFORMATION | 公司資料 | | CHAIRMAN'S STATEMENT | 主席報告書 | | MANAGEMENT DISCUSSION AND ...

美 瑞 健 康 国 际 产 业 集 团 Meilleure Health International Industry Group Meilleure Health International Industry Group Limited 美瑞健康國際產業集團有限公司 ( 於 百 慕 達 達 註 冊 成 立 之 有 限 公 司 ) (股份代號：2327) 一份 专注 两倍 用心 三倍 高效 十重 保障 百倍 体验 终身 受益 美瑞健康一 一 精准健康管理 2019 中期报告 公司資料 2 管理層討論與分析 3 董事及高級管理人員履歷 14 中期簡明綜合損益表 19 中期簡明綜合全面收益表 20 中期簡明綜合財務狀況表 21 中期簡明綜合權益變動表 23 中期簡明綜合現金流量表 24 中期簡明綜合財務報表附註 25 目錄 其他資料 60 1 美瑞健康國際產業集團有限公司 公司資料 | --- | --- | |------------------------------------------------------------------------------------------------------ ...

美 瑞 健 康 国 际 产 业 集 团 Meilleure Health International Industry Group Meilleure Health International Industry Group Limited 美瑞健康國際產業集團有限公司 (Incorporated in Bermuda with limited liability) ( 於 百 慕 達 註 冊 成 立 之 有 限 公 司 ) (Stock Code 股份代號 : 2327) 一份 专注 两倍 用心 三倍 高效 十重 保障 百倍 体验 终身 受益 美瑞健康一 一 精准健康管理 2018 Annual Report 年報 CONTENTS 目 錄 2 4 8 12 23 35 54 58 66 68 70 72 75 216 | --- | --- | |----------------------------------------------------|--------------------------| | | | | Corporate Information | 公司資料 | | Chairman's ...